Brian M. Campbell, Ph.D. - Publications

2001 Wayne State University, Detroit, MI, United States 

27 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2015 Poda SB, Kobayashi M, Nachane R, Menon V, Gandhi AS, Budac DP, Li G, Campbell BM, Tagmose L. Development of a Surface Plasmon Resonance Assay for the Characterization of Small-Molecule Binding Kinetics and Mechanism of Binding to Kynurenine 3-Monooxygenase. Assay and Drug Development Technologies. PMID 26292018 DOI: 10.1089/adt.2015.649  1
2015 Campbell BM, Pocivavsek A, Notarangelo FM, Parachikova AI. Chapter 19: The role of kynurenine pathway metabolites in neuropsychiatric disorders Targeting the Broadly Pathogenic Kynurenine Pathway. 241-254. DOI: 10.1007/978-3-319-11870-3_19  1
2014 Kozak R, Campbell BM, Strick CA, Horner W, Hoffmann WE, Kiss T, Chapin DS, McGinnis D, Abbott AL, Roberts BM, Fonseca K, Guanowsky V, Young DA, Seymour PA, Dounay A, et al. Reduction of brain kynurenic acid improves cognitive function. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 34: 10592-602. PMID 25100593 DOI: 10.1523/JNEUROSCI.1107-14.2014  1
2014 Campbell BM, Charych E, Lee AW, Möller T. Kynurenines in CNS disease: regulation by inflammatory cytokines. Frontiers in Neuroscience. 8: 12. PMID 24567701 DOI: 10.3389/fnins.2014.00012  1
2013 Tuttle JB, Anderson M, Bechle BM, Campbell BM, Chang C, Dounay AB, Evrard E, Fonseca KR, Gan X, Ghosh S, Horner W, James LC, Kim JY, McAllister LA, Pandit J, et al. Structure-Based Design of Irreversible Human KAT II Inhibitors: Discovery of New Potency-Enhancing Interactions. Acs Medicinal Chemistry Letters. 4: 37-40. PMID 24900560 DOI: 10.1021/ml300237v  1
2013 Li G, Jørgensen M, Campbell BM. Metabotropic glutamate receptor 5-negative allosteric modulators for the treatment of psychiatric and neurological disorders (2009-July 2013). Pharmaceutical Patent Analyst. 2: 767-802. PMID 24237242 DOI: 10.4155/ppa.13.58  1
2013 Hopper AT, Jones KA, Campbell BM, Li G. Neuroinflammation in mood disorders: Mechanisms and drug targets Annual Reports in Medicinal Chemistry. 48: 317-331. DOI: 10.1016/B978-0-12-417150-3.00020-X  1
2012 Dounay AB, Anderson M, Bechle BM, Campbell BM, Claffey MM, Evdokimov A, Evrard E, Fonseca KR, Gan X, Ghosh S, Hayward MM, Horner W, Kim JY, McAllister LA, Pandit J, et al. Discovery of Brain-Penetrant, Irreversible Kynurenine Aminotransferase II Inhibitors for Schizophrenia. Acs Medicinal Chemistry Letters. 3: 187-92. PMID 24900455 DOI: 10.1021/ml200204m  1
2012 Li CS, Zhang L, Haske T, Dounay A, Gray D, Barta N, Brodfuehrer J, Lepsy C, Campbell B. Mechanism-based pharmacokinetic/pharmacodynamic modeling of rat prefrontal cortical dopamine response to dual acting norepinephrine reuptake inhibitor and 5-HT1A partial agonist. The Aaps Journal. 14: 365-76. PMID 22454087 DOI: 10.1208/s12248-012-9343-8  1
2012 Hopper AT, Campbell BM, Kao H, Pintchovski SA, Staal RGW. Recent Developments in Targeting Neuroinflammation in Disease Annual Reports in Medicinal Chemistry. 47: 37-53. DOI: 10.1016/B978-0-12-396492-2.00004-7  1
2011 Marder SR, Roth B, Sullivan PF, Scolnick EM, Nestler EJ, Geyer MA, Welnberger DR, Karayiorgou M, Guidotti A, Gingrich J, Akbarian S, Buchanan RW, Lieberman JA, Conn PJ, Haggarty SJ, ... ... Campbell B, et al. Advancing drug discovery for schizophrenia. Annals of the New York Academy of Sciences. 1236: 30-43. PMID 22032400 DOI: 10.1111/j.1749-6632.2011.06216.x  1
2011 Stephenson DT, O'Neill SM, Narayan S, Tiwari A, Arnold E, Samaroo HD, Du F, Ring RH, Campbell B, Pletcher M, Vaidya VA, Morton D. Histopathologic characterization of the BTBR mouse model of autistic-like behavior reveals selective changes in neurodevelopmental proteins and adult hippocampal neurogenesis. Molecular Autism. 2: 7. PMID 21575186 DOI: 10.1186/2040-2392-2-7  1
2011 Pettersson M, Campbell BM, Dounay AB, Gray DL, Xie L, O'Donnell CJ, Stratman NC, Zoski K, Drummond E, Bora G, Probert A, Whisman T. Design, synthesis, and pharmacological evaluation of azetedine and pyrrolidine derivatives as dual norepinephrine reuptake inhibitors and 5-HT(1A) partial agonists. Bioorganic & Medicinal Chemistry Letters. 21: 865-8. PMID 21185183 DOI: 10.1016/j.bmcl.2010.11.066  1
2010 Dounay AB, Barta NS, Campbell BM, Coleman C, Collantes EM, Denny L, Dutta S, Gray DL, Hou D, Iyer R, Maiti SN, Ortwine DF, Probert A, Stratman NC, Subedi R, et al. Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agonists. Bioorganic & Medicinal Chemistry Letters. 20: 1114-7. PMID 20031410 DOI: 10.1016/j.bmcl.2009.12.023  1
2009 Gray DL, Xu W, Campbell BM, Dounay AB, Barta N, Boroski S, Denny L, Evans L, Stratman N, Probert A. Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists. Bioorganic & Medicinal Chemistry Letters. 19: 6604-7. PMID 19854053 DOI: 10.1016/j.bmcl.2009.10.014  1
2009 Dounay AB, Barta NS, Bikker JA, Borosky SA, Campbell BM, Crawford T, Denny L, Evans LM, Gray DL, Lee P, Lenoir EA, Xu W. Synthesis and pharmacological evaluation of aminopyrimidine series of 5-HT1A partial agonists. Bioorganic & Medicinal Chemistry Letters. 19: 1159-63. PMID 19147349 DOI: 10.1016/j.bmcl.2008.12.087  1
2008 Patel SD, Habeski WM, Min H, Zhang J, Roof R, Snyder B, Bora G, Campbell B, Li C, Hidayetoglu D, Johnson DS, Chaudhry A, Charlton ME, Kablaoui NM. Identification and SAR around N-{2-[4-(2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-[1,4]diazepan-1-yl]-ethyl}-2-phenoxy-nicotinamide, a selective alpha2C adrenergic receptor antagonist. Bioorganic & Medicinal Chemistry Letters. 18: 5689-93. PMID 18799310 DOI: 10.1016/j.bmcl.2008.08.055  1
2008 Tannock R, Campbell B, Seymour P, Ouellet D, Soares H, Wang P, Chappell P. Towards a biological understanding of ADHD and the discovery of novel therapeutic approaches Animal and Translational Models For Cns Drug Discovery. 1: 301-351. DOI: 10.1016/B978-0-12-373861-5.00010-2  1
2006 Campbell BM, Kreipke CW, Walker PD. Failure of MK-801 to suppress D1 receptor-mediated induction of locomotor activity and striatal preprotachykinin mRNA expression in the dopamine-depleted rat. Neuroscience. 137: 505-17. PMID 16289829 DOI: 10.1016/j.neuroscience.2005.09.024  1
2004 Béïque JC, Campbell B, Perring P, Hamblin MW, Walker P, Mladenovic L, Andrade R. Serotonergic regulation of membrane potential in developing rat prefrontal cortex: coordinated expression of 5-hydroxytryptamine (5-HT)1A, 5-HT2A, and 5-HT7 receptors. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 24: 4807-17. PMID 15152041 DOI: 10.1523/JNEUROSCI.5113-03.2004  1
2004 Campbell BM, Morrison JL, Walker EL, Merchant KM. Differential regulation of behavioral, genomic, and neuroendocrine responses by CRF infusions in rats. Pharmacology, Biochemistry, and Behavior. 77: 447-55. PMID 15006454 DOI: 10.1016/j.pbb.2003.12.010  1
2003 Campbell BM, Merchant KM. Serotonin 2C receptors within the basolateral amygdala induce acute fear-like responses in an open-field environment. Brain Research. 993: 1-9. PMID 14642825 DOI: 10.1016/S0006-8993(03)03384-5  1
2002 Campbell BM, Walker PD. Striatal tachykinin and enkephalin mRNAs are normalized by serotonin2 and NMDA manipulation following dopamine depletion. Neuroreport. 13: 5-8. PMID 11924893  1
2001 Campbell BM, Walker PD. NMDA receptor antagonism modifies the synergistic regulation of striatal tachykinin gene expression induced by dopamine D(1) and serotonin(2) receptor stimulation following neonatal dopamine depletion. Brain Research. Molecular Brain Research. 93: 90-4. PMID 11532342 DOI: 10.1016/S0169-328X(01)00156-5  1
2001 Campbell BM, Gresch PJ, Walker PD. Neonatal dopamine depletion reveals a synergistic mechanism of mRNA regulation that is mediated by dopamine(D1) and serotonin(2) receptors and is targeted to tachykinin neurons of the dorsomedial striatum. Neuroscience. 105: 671-80. PMID 11516832 DOI: 10.1016/S0306-4522(01)00218-4  1
2001 Campbell BM, Walker PD. MK-801 prevents dopamine D1 but not serotonin 2A stimulation of striatal preprotachykinin mRNA expression. Neuroreport. 12: 953-5. PMID 11303767  1
2001 Campbell BM, Walker PD. Striatal preprotachykinin mRNA levels are regulated by stimulatory agents and dopamine D1 receptor manipulation in rodent organotypic slice cultures. Brain Research. 888: 26-33. PMID 11146049 DOI: 10.1016/S0006-8993(00)02997-8  1
Show low-probability matches.